Follow-up study for people who received gene-carrying viral vaccines
Part of Cancer, Digestive system, Kidney & urinary, Lungs & breathing, Skin clinical trials.
This is a follow-up study for adults who previously received certain viral vaccines that carry genes (such as vaccinia or fowlpox) through NCI trials or partner sites. The goal is to store and use your leftover samples for future research that may help doctors understand these treatments better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 18 or older.
- You must have previously received a poxvirus-based gene-carrying vaccine (or a similar gene-transfer vaccine) through an NCI study.
- Your previous treatment may have been done at NCI or at an outside site as part of a multi-site study.
- If you have stored samples from an earlier NCI study, the study may move them to this study for storage.
- You must be willing to participate in this follow-up study (and allow sample transfer/storage if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects and stores tissue from people with breast cancer or other gynecologic cancers to do DNA (genomics) testing. It may help researchers better understand these cancers by comparing genetic patterns from real patient tissue.
This study collects prostate tissue samples from men who are either at higher risk due to a gene change or are getting a biopsy or prostate surgery for routine care. The samples are stored in a biobank for future research on prostate cancer.
This study looks at how Veterans with advanced prostate cancer make decisions about gene testing and possible targeted treatments, and how patients and caregivers understand the information. It may help by improving decision support for people facing germline and tumor testing choices.
This study looks at how prostate cancer diagnoses and treatments turn out over time. It compares men who carry rare inherited gene changes that raise prostate cancer risk with men who do not, to better understand which treatments and outcomes may differ.
This trial tests a new treatment where a virus (GC001) is injected directly into a tumor. The virus is designed to attack cancer cells and may help people with advanced solid tumors that haven't responded to other treatments.
This study looks at stored tumor samples to understand why some people respond much better or much worse than expected. The goal is to learn what the tumor’s genes might be telling doctors about response to treatment.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.